DelveInsight’s “Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tuberous Sclerosis Complex market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Tuberous Sclerosis Complex drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Tuberous Sclerosis Complex treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Tuberous Sclerosis Complex: An Overview
Tuberous Sclerosis Complex (TSC) is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. These tumors can occur in the skin, brain, kidneys, and other organs, in some cases leading to significant health problems. Tuberous sclerosis complex also causes developmental problems, and the signs and symptoms of the condition vary from person to person. Virtually all affected people have skin abnormalities, including patches of unusually light-colored skin, areas of raised and thickened skin, and growths under the nails. Tumors on the face called facial angiofibromas are also common beginning in childhood.
TSC can affect many different systems of the body, causing a variety of signs and symptoms that range from very mild to quite severe.
Tuberous Sclerosis Complex Market Key Facts
According to the National Institutes of Health, Tuberous sclerosis complex affects about 1 in 6,000 people.
As per the National Organization for Rare Disorders, Tuberous sclerosis is a rare genetic disorder that affects 1 in 6,000 newborns in the United States. Approximately 40,000 to 80,000 people in the United States have tuberous sclerosis. The prevalence in Europe is estimated to be approximately 1 in 25,000 to 1 in 11,300. As many as 2 million people worldwide are believed to have the disorder.
As per a study conducted by Cockerell et al., 2017, renal manifestations are present in 48%-85% of TSC patients and include angiomyolipomas (AMLs), cysts, and, to a lesser degree, development of renal cancers or progression toward renal insufficiency in French patients.
As per the study by Graffigna et al. 2013, Tuberous Sclerosis Complex affects approximately 5000 individuals in Italy.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Tuberous Sclerosis Complex pipeline therapies. It also thoroughly assesses the Tuberous Sclerosis Complex market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Tuberous Sclerosis Complex drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Tuberous Sclerosis Complex Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Tuberous Sclerosis Complex epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Tuberous Sclerosis Complex epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Tuberous Sclerosis Complex Epidemiology, Segmented as –
Prevalent cases of Tuberous Sclerosis Complex in 7MM (2019–2032)
Clinical Manifestations-specific Prevalent Cases of Tuberous Sclerosis Complex in 7MM (2019–2032)
Diagnosed and Treatable Cases of Tuberous Sclerosis Complex in the 7MM (2019–2032)
Severity-specific Prevalent Cases of Tuberous Sclerosis Complex in 7MM (2019–2032)
Tuberous Sclerosis Complex Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Tuberous Sclerosis Complex market or expected to be launched during the study period. The analysis covers the Tuberous Sclerosis Complex market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Tuberous Sclerosis Complex drugs based on their sale and market share.
The report also covers the Tuberous Sclerosis Complex pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Tuberous Sclerosis Complex companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Tuberous Sclerosis Complex Market Will Evolve and Grow by 2032 @
Tuberous Sclerosis Complex Therapeutics Analysis
There is no cure for TSC, although treatment is available for a number of the symptoms. Early diagnosis and intervention can help overcome developmental delays. Data show that early seizure control in children can improve learning as compared to children without good seizure control. Advancements in research continue to bring new and improved therapeutic options. Some anti-seizure drugs can be effective in individuals with TSC. When drug treatment fails to adequately control seizures, technology can help identify the exact portions of the brain-stimulating seizures to help decide if surgery may be a good approach for an individual.
The management of TSC is directed at its neurologic and systemic manifestations, which include seizures, TSC-associated neuropsychiatric disorders, brain tumors, skin lesions, renal disease, pulmonary disease, cardiac involvement, and an increased risk of malignant tumors. Information regarding therapeutic interventions for these problems is provided in the sections that follow.
To redress the current issues, a few companies like Takeda Pharmaceuticals, Aucta Pharmaceuticals, Inc., GW Pharmaceuticals, and others are currently working toward this indication to meet the needs of the market. Apart from this, scientists who study TSC seek to increase their understanding of the disorder by learning more about the TSC1 and TSC2 genes that can cause the disorder and the function of the proteins-tuberin and hamartin-produced by these genes.
Tuberous Sclerosis Complex Companies Actively Working in the Therapeutics Market Include
Ovid Therapeutics Inc.
GW Research Ltd.
And Many Others
Emerging and Marketed Tuberous Sclerosis Complex Therapies Covered in the Report Include:
Everolimus (Afinitor): Novartis Pharma
Vigabatrin (Sabril): Lundbeck
TAK-935: Takeda/Ovid Therapeutics Inc.
GWP42003-P: GW Research Ltd.
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Tuberous Sclerosis Complex Competitive Intelligence Analysis
4. Tuberous Sclerosis Complex Market Overview at a Glance
5. Tuberous Sclerosis Complex Disease Background and Overview
6. Tuberous Sclerosis Complex Patient Journey
7. Tuberous Sclerosis Complex Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Tuberous Sclerosis Complex Treatment Algorithm, Current Treatment, and Medical Practices
9. Tuberous Sclerosis Complex Unmet Needs
10. Key Endpoints of Tuberous Sclerosis Complex Treatment
11. Tuberous Sclerosis Complex Marketed Therapies
12. Tuberous Sclerosis Complex Emerging Drugs and Latest Therapeutic Advances
13. Tuberous Sclerosis Complex Seven Major Market Analysis
14. Attribute Analysis
15. Tuberous Sclerosis Complex Market Outlook (In US, EU5, and Japan)
16. Tuberous Sclerosis Complex Companies Active in the Market
17. Tuberous Sclerosis Complex Access and Reimbursement Overview
18. KOL Views on the Tuberous Sclerosis Complex Market
19. Tuberous Sclerosis Complex Market Drivers
20. Tuberous Sclerosis Complex Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Tumor Ablation Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tumor Ablation market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Tumor Ablation market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States